NeOnc Q4 net loss $62.1M ($3.20/sh); NEO212 Phase 1 complete, NEO100 Phase 2a enrolled

NEONC TECHNOLOGIES HOLDINGS, INC.

Q4 net loss $62.1M ($3.20 diluted EPS) vs $11.9M ($0.69) in Q4 2024; G&A surged to $4.8M from $1.7M.
NEO212 Phase 1 complete; RP2D set at 610 mg; company plans Type B End-of-Phase 1 FDA meeting for potential registrational study.
NEO100 Phase 2a fully enrolled in IDH1-mutant high-grade glioma; interim data readout expected ~August 2026.
PIPE financing anchored by $10M commitment from Cinctive Capital Management.
Leadership additions: Amir Heshmatpour named CEO, David Choi appointed CAO; two neuro-oncologists joined SAB.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

NEONC TECHNOLOGIES HOLDINGS, INC. reported the quarter and year ended December 31, 2025 results: net income $62.1 million or $3.20 per diluted share, EPS $3.20 per diluted share.

Period: the quarter and year ended December 31, 2025
Net income: $62.1 million or $3.20 per diluted share
EPS: $3.20 per diluted share
Result: reported results

Exact text from the filing

$3,045k in Q4 2024, driven by active management of NEO100 trial sites, recruitment for NEO212, initiation of NEO100-3, and overall patient recruitment activity. ● Net loss: $62.1 million or $3.20 per diluted share, compared to $11.9 million or $0.69 per diluted share in Q4 2024, primarily due to increased general and administrative expenses, as well as

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

NEONC TECHNOLOGIES HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001829126-26-003165

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.